CINA CHEST vs KardiaAI

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

CINA CHEST

by Avicenna.AI

KardiaAI

by AliveCor

AI Verdict

CINA CHEST is designed for rapid radiological triage of life-threatening conditions like pulmonary embolism and aortic dissection using CT angiography scans. In contrast, KardiaAI focuses on analyzing ambulatory ECG rhythms to detect various cardiac arrhythmias such as AFib, bradycardia, and tachycardia. While both are FDA-cleared AI tools relevant to cardiology and emergency medicine, they address distinct diagnostic needs and utilize different data modalities.

Choose CINA CHEST if…

Choose CINA CHEST if your emergency department or radiology practice requires immediate, AI-powered triage for life-threatening chest conditions detected on CT angiography scans. This tool is ideal for rapidly identifying and prioritizing cases of Pulmonary Embolism and Aortic Dissection to streamline workflow and accelerate critical patient care.

View CINA CHEST →

Choose KardiaAI if…

Choose KardiaAI if you need an FDA-cleared AI software library for comprehensive analysis of ambulatory ECG rhythms, particularly for detecting a wide range of cardiac conditions like AFib, bradycardia, and tachycardia. This solution is best suited for integration into mobile apps or other ECG devices to provide ongoing, medical-grade heart rhythm data analysis for patients or clinicians.

View KardiaAI →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	CINA CHEST	KardiaAI
Pricing	Subscription-based	Subscription-based for integrated services
Deployment	Cloud-based, On-premise (dedicated hardware), Virtualized (VM, Docker)	Software as a Medical Device (SaMD), API library integrated into mobile apps and web platforms
FDA Status	K210237 AI-estimated	1 AI-estimated
HIPAA	Yes AI-estimated	Unknown

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

CINA CHEST

CINA CHEST operates as a standalone web application, offering a direct user interface designed for radiologists in a workflow triage setting. KardiaAI, as an API library, relies on integration into other mobile and web platforms, meaning its direct usability is dependent on third-party implementation and can vary widely.

Clinical Value

CINA CHEST

Both tools are FDA-cleared and offer significant clinical value in their respective domains. CINA CHEST focuses on rapid triage and notification for acute, life-threatening conditions like Pulmonary Embolism and Aortic Dissection on CT scans, directly impacting emergency decision-making and patient outcomes in critical situations. While KardiaAI detects a broader range of cardiac conditions from ECGs, CINA CHEST's explicit role in emergency triage for highly morbid conditions gives it a slight edge in immediate, high-stakes clinical impact.

Pricing & Value

KardiaAI

KardiaAI provides clear and transparent subscription pricing for its KardiaCare services, offering monthly and annual options. In contrast, CINA CHEST's pricing is listed as 'subscription-based; details available upon request,' which lacks transparency for direct comparison and value assessment.

Enterprise Readiness

CINA CHEST

CINA CHEST offers flexible deployment options including cloud-based, on-premise (dedicated hardware), and virtualized environments (VM, Docker), which are crucial for integrating into diverse hospital network IT infrastructures. It is explicitly designed to assist hospital networks and trained radiologists in workflow triage. KardiaAI, while HIPAA compliant and offering an API, is primarily an API library, which may require more custom development for full enterprise integration and management.

Innovation

KardiaAI

While both leverage advanced AI, KardiaAI's KAI 12L AI technology and Kardia 12L ECG System are described as the 'world's first AI-powered, handheld 12-lead electrocardiogram (ECG) system with a unique single-cable design' capable of detecting 35 cardiac conditions, including heart attacks, using a reduced leadset. This significantly expands access to advanced ECG diagnostics in various settings, including resource-limited ones, representing a major leap in accessible cardiac care.

Support & Docs

KardiaAI

AliveCor (KardiaAI) offers extensive and publicly accessible support documentation, including detailed FAQs, troubleshooting guides, and user manuals available in multiple languages for its various Kardia devices and app. Avicenna.AI (CINA CHEST) provides contact information and emphasizes regulatory compliance, but less specific, user-facing support documentation is readily available online.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	CINA CHEST	KardiaAI
Name	CINA CHEST	KardiaAI
Company	Avicenna.AI	AliveCor
Primary Function	AI-powered radiological triage and notification software for rapid detection and prioritization of Pulmonary Embolism (PE) and Aortic Dissection (AD) on CT angiography scans.	AI software library for analyzing ambulatory ECG rhythms, detecting various cardiac conditions like AFib, bradycardia, and tachycardia.
Target Conditions Detected	Pulmonary Embolism (PE), Aortic Dissection (AD)	Atrial fibrillation, bradycardia, tachycardia, normal sinus rhythm, Sinus Rhythm with Premature Ventricular Contractions (PVCs), Sinus Rhythm with Wide QRS, Sinus Rhythm with Supraventricular Ectopy (SVE)
Input Data Type	CT angiography scans	Ambulatory ECG rhythms

Videos

Demos, reviews, and walkthroughs featuring CINA CHEST and KardiaAI.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do CINA CHEST and KardiaAI integrate into existing clinical workflows for physicians, given their distinct applications?

CINA CHEST is designed to integrate seamlessly into existing radiology workflows, automatically flagging suspected PE and AD findings on CT scans and communicating them to assist in triage without requiring changes to clinical workflows or additional viewers. KardiaAI, as an API library, integrates into mobile apps and web platforms, allowing for the analysis of ambulatory ECG rhythms and can pull ECGs into EHR systems like Epic and GE Healthcare's MUSE for physician review.

What are the key differences in accuracy and clinical utility for CINA CHEST and KardiaAI, considering their respective conditions?

CINA CHEST focuses on the rapid detection and prioritization of life-threatening conditions like Pulmonary Embolism (PE) and Aortic Dissection (AD) on CT angiography scans, with reported sensitivities of 91.1-96.4% and specificities of 91.8-97.5% for these conditions. KardiaAI analyzes ambulatory ECG rhythms to detect various cardiac conditions such as AFib, bradycardia, and tachycardia, with studies showing its AFib detection algorithm having a sensitivity between 77.0% and 96.6% and specificity between 76.0% and 99.1%.

What is the expected learning curve for physicians and staff to effectively utilize each tool, and how quickly can clinical benefits be realized?

CINA CHEST is designed for minimal operational friction, integrating automatically into PACS and RIS without requiring new viewers, worklists, additional clicks, or extra training for clinicians. KardiaAI, particularly with devices like KardiaMobile, has been noted for its ease of use by both patients and physicians, facilitating quicker diagnoses for conditions like AFib compared to standard care.

Beyond HIPAA, what specific security measures and audit-trail features are in place for each tool to ensure data privacy and integrity?

Avicenna.AI's platform, which includes CINA CHEST, is built with security at its core, supporting GDPR- and HIPAA-compliant workflows by de-identifying data before processing and re-identifying it upon return, with encryption, access controls, and auditable operations. AliveCor, for KardiaAI, states it protects customers with stringent data security and compliance practices, achieving HIPAA compliance, SOC2 Type 1 and Type 2 attestations, ISO 27001, ISO 42001, and HITRUST e1 Certification.

How do these tools support multi-site rollout considerations, and are customer references or case studies available to demonstrate real-world implementation?

CINA CHEST, through Avicenna.AI's AVI platform, is designed for scalability, integrating seamlessly into existing healthcare systems via global standards like DICOM, HL7, and FHIR, and can be deployed across single sites to large networks. AliveCor provides a resource hub with case studies and clinical validation studies demonstrating the impact of KardiaMobile in various settings and its integration into EHR systems.

What is the clinical context in which each tool provides the most significant value for a physician?

CINA CHEST offers significant value in emergency radiology by providing rapid, AI-powered triage and notification for acute, life-threatening conditions such as Pulmonary Embolism and Aortic Dissection on CT scans, aiding in faster decision-making and intervention. KardiaAI is most valuable in cardiology, emergency medicine, and internal medicine for analyzing ambulatory ECG rhythms to detect and manage various cardiac conditions like AFib, bradycardia, and tachycardia, particularly for remote patient monitoring and early diagnosis.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring CINA CHEST or KardiaAI

Backers

Who funded each tool's parent company.